Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel Sells 40,000 Shares

Moderna, Inc. (NASDAQ:MRNA – Get Rating) CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $131.43, for a total value of $5,257,200.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $711,292,062.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Stephane Bancel also recently made the following trade(s):

• On Wednesday, May 10th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $131.60, for a total value of $5,264,000.00.
• On Thursday, April 27th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $130.61, for a total value of $5,224,400.00.
• On Thursday, April 20th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $142.99, for a total value of $5,719,600.00.
• On Wednesday, April 12th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $156.68, for a total value of $6,267,200.00.
• On Wednesday, April 5th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $154.64, for a total value of $6,185,600.00.
• On Thursday, March 30th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $148.63, for a total value of $5,945,200.00.
• On Wednesday, March 22nd, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $150.25, for a total value of $6,010,000.00.
• On Thursday, March 16th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $150.87, for a total value of $6,034,800.00.
• On Thursday, March 9th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $139.20, for a total value of $5,568,000.00.
• On Thursday, March 2nd, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $137.50, for a total value of $5,500,000.00.

Moderna Trading Down 0.2 %

MRNA traded down $0.23 during mid-day trading on Friday, hitting $126.24. 3,640,395 shares of the stock were exchanged, compared to its average volume of 3,584,716. The firm’s fifty day moving average is $142.10 and its two-hundred day moving average is $163.47. Moderna, Inc. has a 1-year low of $115.03 and a 1-year high of $217.25. The company has a current ratio of 3.46, a quick ratio of 3.26 and a debt-to-equity ratio of 0.04. The company has a market cap of $48.12 billion, a PE ratio of 10.93 and a beta of 1.70.

Moderna (NASDAQ:MRNA – Get Rating) last posted its earnings results on Thursday, May 4th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.77) by $1.96. Moderna had a return on equity of 25.87% and a net margin of 31.77%. The firm had revenue of $1.86 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the company earned $8.58 EPS. Moderna’s revenue was down 69.3% on a year-over-year basis. Equities analysts forecast that Moderna, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Morgan Stanley dropped their price target on Moderna from $185.00 to $153.00 in a research report on Friday, May 5th. Royal Bank of Canada assumed coverage on Moderna in a research report on Wednesday, March 1st. They set an “outperform” rating and a $200.00 price target for the company. Deutsche Bank Aktiengesellschaft dropped their target price on Moderna from $225.00 to $200.00 and set a “buy” rating for the company in a report on Tuesday, February 28th. SVB Leerink cut Moderna from a “market perform” rating to an “underperform” rating and dropped their target price for the company from $111.00 to $93.00 in a report on Friday, February 24th. Finally, SVB Securities cut Moderna from a “market perform” rating to an “underperform” rating and dropped their target price for the company from $111.00 to $93.00 in a report on Friday, February 24th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $179.13.

Hedge Funds Weigh In On Moderna

Hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new stake in Moderna in the 4th quarter valued at about $628,359,000. Price T Rowe Associates Inc. MD raised its position in Moderna by 89.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 6,443,409 shares of the company’s stock valued at $761,934,000 after purchasing an additional 3,051,035 shares in the last quarter. Renaissance Technologies LLC raised its position in Moderna by 108.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares in the last quarter. Baillie Gifford & Co. raised its position in Moderna by 3.7% in the 1st quarter. Baillie Gifford & Co. now owns 46,466,171 shares of the company’s stock valued at $7,136,275,000 after purchasing an additional 1,679,425 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its position in Moderna by 699.3% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,538,506 shares of the company’s stock valued at $26,205,000 after purchasing an additional 1,346,028 shares in the last quarter. Institutional investors and hedge funds own 63.11% of the company’s stock.

About Moderna

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.